Invenra To Feature Cancer Patient Art in Upcoming Antibody Therapy Development Project

Artists Earn a $1,000 Stipend While Inspiring Drug Discovery

MADISON, Wis.--(BUSINESS WIRE)--Invenra, Inc., a biotechnology company pioneering multispecific antibody therapeutics, is requesting cancer patient and survivor artwork, which will be featured in an innovative project linking patient experiences to people doing important cancer research and development.

If selected, artists will earn a $1,000 stipend and have their work featured in a one-of-a-kind playing card deck that celebrates the creativity, resilience, and spirit of people whose lives have been touched by cancer.

Each of the 52 cards in this deck will feature original artwork from a different cancer patient or survivor, making every card a unique view of the human experience with this disease. Cards will correspond with potential novel cancer therapies envisioned by Invenra scientists.

“This is an art-forward deck where the artwork is the hero. We will print several thousand decks and distribute them at major scientific and medical conferences, placing patient’s voices and visions directly into the hands of the researchers, clinicians, and scientists who are working to cure the cancers these artists have faced,” said Roland Green, Invenra CEO and founder.

Anyone who has faced cancer, regardless of location, age or experience level, is eligible to submit original art, no AI-generated art, please. The deadline for submissions is June 1, 2026. Selected artists will retain rights to the art and receive complimentary decks.

To learn more about our call for art or submit your artwork, visit 52 Views of Cancer.

About Invenra

Invenra is a Madison, Wisconsin-based biotechnology company focused on the discovery and development of multispecific antibody therapeutics. Invenra employs its extensive technology toolbox and efficient discovery engine to design and create first- and best-in-class drug candidates. The Invenra T-Body™ platform expands these capabilities for efficient expression, correct chain pairing, and robust assembly of trispecific constructs. Invenra partners globally with pharmaceutical and biotech companies to accelerate therapeutic antibody programs from discovery through preclinical development. For more information, visit www.invenra.com.